AstraZeneca’s pause of its COVID-19 vaccine trial is a “wake-up call” demonstrating the challenges of the development process, according to the World Health Organization’s chief scientist.<
Shares in California biotech Satsuma Pharma have lost three quarters of their value after lead drug STS01 failed to show any improvement over placebo in an acute migraine study.
AstraZeneca’s Fasenra (benralizumab) injected drug cuts the size of nasal polyps and nasal blockage in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Two UK biotechs – Destiny Pharma and Sporegen – have joined forces to develop a nasal spray that they say could serve as a first line of defense against COVID-19 infections.
AstraZeneca’s decision to halt all its phase 3 trials of COVID-19 vaccine AZD1222 after an adverse reaction in a single UK volunteer may end up just being a precautionary measure, but could
US biotech Insmed has trumpeted updated phase 2 data from its brensocatib, at this week’s virtual European Respiratory Society conference, showing the drug prolonged time to exacerbations c